We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Diabetes Drug Shows Promise as an Anticancer Immunotherapeutic Agent

By LabMedica International staff writers
Posted on 30 Jun 2015
Print article
Image: Histological section of two mouse melanomas: (a) untreated and (b) treated with sitagliptin, a specific DPP4 inhibitor (Photo courtesy of Institut Pasteur).
Image: Histological section of two mouse melanomas: (a) untreated and (b) treated with sitagliptin, a specific DPP4 inhibitor (Photo courtesy of Institut Pasteur).
Treatment with the anti-diabetes drug sitagliptin of some types of cancer in a mouse model was found to increase the infiltration of T lymphocytes into tumors and, in combination with existing immunotherapies, eradicate the tumor.

Sitagliptin modulates diabetes symptoms by competitively inhibiting the enzyme dipeptidylpeptidase 4 (DPP4). This enzyme breaks down the incretins GLP-1 and GIP, gastrointestinal hormones released in response to a meal. By preventing GLP-1 and GIP inactivation, they are able to increase the secretion of insulin and suppress the release of glucagon by the alpha cells of the pancreas, which drives blood glucose levels towards normal. As the blood glucose level approaches normal, the amounts of insulin released and glucagon suppressed diminishes, thus preventing hypoglycemia, which is seen with some other oral hypoglycemic agents.

Investigators at Institut Pasteur (Paris, France) reported in the June 15, 2015, online edition of the journal Nature Immunology that inhibition of DPP4 enzymatic activity in mice by oral administration of sitagliptin enhanced tumor rejection by preserving biologically active CXCL10 and increasing trafficking into the tumor by lymphocytes expressing the counter-receptor CXCR3.

CXCL10 (C-X-C motif chemokine 10 also known as interferon gamma-induced protein 10) is secreted by several cell types in response to IFN-gamma. These cell types include monocytes, endothelial cells, and fibroblasts. CXCL10 has been linked to several functions, such as chemoattraction for monocytes/macrophages, T-cells, NK cells, and dendritic cells, promotion of T-cell adhesion to endothelial cells, antitumor activity, and inhibition of bone marrow colony formation and angiogenesis.

This chemokine elicits its effects by binding to the cell surface chemokine receptor CXCR3.

DPP4 inhibition improved adjuvant-based immunotherapy, adoptive T-cell transfer, and checkpoint blockade, findings that provide direct in vivo evidence to support the use of DPP4 inhibitors for stabilizing biologically active forms of chemokines as a strategy to enhance tumor immunotherapy.

Related Links:

Institut Pasteur


New
Gold Member
Syphilis Screening Test
VDRL Antigen MR
Automated Blood Typing System
IH-500 NEXT
New
Chemistry Analyzer
MS100
New
Vitamin B12 Test
CHORUS CLIA VIT B12

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.